MA31927B1 - Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives - Google Patents

Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Info

Publication number
MA31927B1
MA31927B1 MA32934A MA32934A MA31927B1 MA 31927 B1 MA31927 B1 MA 31927B1 MA 32934 A MA32934 A MA 32934A MA 32934 A MA32934 A MA 32934A MA 31927 B1 MA31927 B1 MA 31927B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
compositions containing
digestive enzymes
active protein
protein base
Prior art date
Application number
MA32934A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Farid Bennis
Jean-Jacques Serrano
Original Assignee
Farid Bennis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farid Bennis filed Critical Farid Bennis
Publication of MA31927B1 publication Critical patent/MA31927B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA32934A 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives MA31927B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (1)

Publication Number Publication Date
MA31927B1 true MA31927B1 (fr) 2010-12-01

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32934A MA31927B1 (fr) 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Country Status (19)

Country Link
US (1) US8309123B2 (enExample)
EP (1) EP2234598B1 (enExample)
JP (1) JP5676272B2 (enExample)
KR (2) KR101592609B1 (enExample)
CN (1) CN101917967B (enExample)
AP (1) AP3573A (enExample)
AR (1) AR069847A1 (enExample)
AU (1) AU2008345474B2 (enExample)
BR (1) BRPI0821373B8 (enExample)
CA (1) CA2709899C (enExample)
EA (1) EA023107B1 (enExample)
ES (1) ES3055634T3 (enExample)
FR (1) FR2925333B1 (enExample)
IL (1) IL206364A (enExample)
MA (1) MA31927B1 (enExample)
MX (1) MX2010006927A (enExample)
TN (1) TN2010000290A1 (enExample)
TW (1) TWI461226B (enExample)
WO (1) WO2009083686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
EP3215128B1 (en) 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2005113008A1 (en) * 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
PL1883394T3 (pl) 2005-05-23 2018-09-28 Sdg, Inc. Konstrukt lipidowy do dostarczania insuliny ssakowi
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20070134332A1 (en) * 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
WO2009083686A9 (fr) 2009-10-15
HK1146386A1 (en) 2011-06-03
US20090176691A1 (en) 2009-07-09
KR20100095449A (ko) 2010-08-30
ES3055634T3 (en) 2026-02-13
EP2234598C0 (fr) 2025-11-19
AP2010005298A0 (en) 2010-06-30
CN101917967A (zh) 2010-12-15
BRPI0821373B1 (pt) 2020-04-22
JP5676272B2 (ja) 2015-02-25
FR2925333A1 (fr) 2009-06-26
US8309123B2 (en) 2012-11-13
TWI461226B (zh) 2014-11-21
EA201070746A1 (ru) 2011-02-28
EP2234598A1 (fr) 2010-10-06
IL206364A0 (en) 2010-12-30
CA2709899A1 (fr) 2009-07-09
FR2925333B1 (fr) 2012-04-13
TN2010000290A1 (fr) 2011-11-11
AU2008345474A1 (en) 2009-07-09
TW200940107A (en) 2009-10-01
IL206364A (en) 2016-12-29
CA2709899C (fr) 2018-01-16
BRPI0821373B8 (pt) 2021-05-25
EP2234598B1 (fr) 2025-11-19
AU2008345474B2 (en) 2014-07-31
EA023107B1 (ru) 2016-04-29
WO2009083686A1 (fr) 2009-07-09
KR101592609B1 (ko) 2016-02-05
BRPI0821373A2 (pt) 2015-06-16
AR069847A1 (es) 2010-02-24
MX2010006927A (es) 2010-12-06
JP2011506587A (ja) 2011-03-03
CN101917967B (zh) 2013-05-22
AP3573A (en) 2016-02-08
KR20150132887A (ko) 2015-11-26

Similar Documents

Publication Publication Date Title
MA31927B1 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
Kim et al. Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm
Mandl‐Weber et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
TW200600118A (en) Pharmaceutical suspension composition
WO2007109260A3 (en) Silicone elastomer gels
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
IL190646A0 (en) Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
SG155163A1 (en) Pharmacokinetically improved compounds
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
SG165314A1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
EP2292220A3 (en) Composition and methods for increasing insulin sensitivity
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
BRPI0410701A (pt) produto farmacêutico estabilizado
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
ES2720954T3 (es) Formulaciones estabilizadas de estatina
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
AU2008207317A8 (en) HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity
FR2884252B1 (fr) Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant